	Substitute Form PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office		Attorney's Docket No. Application No. 20750-048US1 10/576,849		
	Information Disclosure Statement by Applicant		Applicant Brian Smith, et al.		
(Use several sheets if necessary)		Filing Date April 9, 2007	Group Art Unit		

			U.S. Pate	nt Documents			
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	Al	US 3652543	3/28/72	Hoegerle			
	A2	US 3716639	2/13/73	Hoegerle et al.			
	A3	US 3795683	3/05/74	Brossi et al.			
	A4	US 4108989	8/22/78	Holden			
	A5	US 4111957	9/05/78	Holden et al.			
	A6	US 4210749	7/01/80	Shetty			
	A7	US 4210729	7/01/80	Bola V. Shetty			
	A8	US 4233217	11/11/80	Shetty			
	A9	US 4477378	10/16/84	Gold et al.			
	A10	US 5387685	2/07/85	Powell et al.			
	A11	US 4762845	8/09/88	Chu et al.			
	A12	US 4988690	1/29/91	Effland et al.			
	A13	US 5015639	5/14/91	Berger et al.			
	A14	US 5178786	1/12/93	Jahnke et al.			
	A15	US 5387685	7/16/93	Powell et al.			
	A16	US 5275915	1/04/94	Kojima et al.			
	A17	US 5412119	5/02/95	Brussee et al.			
	A18	US 5422355	6/06/95	White et al.			
	A19	US 5691362	11/25/97	McCormick et al.			
	A20	US 5750520	5/12/98	Danilewicz et al.			
	A21	US 5856503	1/05/99	Aebi et al.			
	A22	US 5861393	1/19/99	Danilewicz et al.			
	A23	US 5925651	7/20/99	Hutchinson			
	A24	US 5939415	8/17/99	Laufer et al.			
	A25	US 5942535	8/24/99	Laufer et al.			
	A26	US 5958943	9/28/99	Laufer et al.			
	A27	US 6087346	7/11/00	Glennon et al.			

Examiner Signature	Date Considered

	Substitute Form PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office		Attorney's Docket No. 20750-048US1	Application No. 10/576,849
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.99(b))		Applicant Brian Smith, et al.		
		Filing Date April 9, 2007	Group Art Unit	

	U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate	
	A28	US 6218385	4/17/01	Adam et al.				
	A29	US 6218385	4/17/01	Geo Adam et al.				
	A30	US 6900313	5/31/05	Wasserscheid et al.				
	A31	US 6953787	10/11/05	Smith et al.				
	A32	US 6972295	12/06/05	Hagmann et al.				
	A33	2007/0275949	11/29/07	Smith et al.				

Foreign Patent Documents or Published Foreign Patent Applications Examiner Desig. Publication Country or Translation Initial ID` Document Number Date Patent Office Class Subclass Yes No A34 DE 1944121 3/19/70 Germany A35 CH 500194 1/29/71 Switzerland United A36 GB 1221324 2/03/71 Kingdom United A37 GB 1225053 3/17/71 Kingdom United GB 1268243 3/22/72 A38 Kingdom A39 NL 7807819 7/21/78 Netherlands A40 EP 0007070 1/23/80 Europe A41 CA 1090797 12/02/80 Canada United A42 GB 1599705 10/07/81 Kingdom A43 EP 0080779 A1 6/08/83 Europe A44 DE 3315106 A1 11/03/83 Germany A45 EP 0096838 A1 12/28/83 Europe A46 EP 0161350 A1 11/21/85 Europe A47 EP 0174118 A2 3/12/86 Europe A48 EP 0285287 A3 3/23/87 Europe A49 EP 0285919 10/12/88 Europe A50 WO 8807858 10/20/88 WIPO

Examiner Signature	Date Considered
CVAMINED. Initials situation considered Drawline through situation if no	Construction of the Constr

next communication to applicant.

Substitute Form PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office		Attorney's Docket No. 20750-048US1	Application No. 10/576,849
	losure Statement plicant	Applicant Brian Smith, et al.	
,	eets if necessary)	Filing Date April 9, 2007	Group Art Unit
(37 CFR §1.98(b))		11pm 7, 2007	

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Desig.			Publication	Country or				slation
Initial	_ID	Document Number	Date	Patent Office	Class	Subclass	Yes	No
	A51	EP 0331130	09/06/89	Europe				
	A52	WO 9119698	12/26/91	WIPO				
	A53	WO 9300094	1/07/93	WIPO				
	A54	WO 93/03015	2/18/93	WIPO				
	A55	JP 5339263	12/21/93	Japan				
	A56	JP 06298746	10/25/94	Japan				
	A57	WO 9513274	5/18/95	WIPO				
	A58	CA 2197789	8/16/95	Canada				
	A59	WO 9604271	2/15/96	WIPO				
	A60	WO 9605194	2/22/96	WIPO				
	A61	JP 08134048	5/28/96	Japan				
	A62	WO 9633993	10/31/96	WIPO				
	A63	JP 09030960	2/04/97	Japan				
	A64	JP 90987258	3/31/97	Japan				
	A65	WO 97/24364	7/10/97	WIPO				
	A66	WO 9806701	2/19/98	WIPO				
	A67	WO 9840385	9/17/98	WIPO				
	A68	WO 99/24411	5/20/99	WIPO				
	A69	EP 0987235 A1	3/22/00	Europe				
	A70	EP 1074549 A2	2/07/01	Europe				
	A71	WO 0240471	5/23/02	WIPO				
	A72	WO 0248124	6/20/02	WIPO				
	A73	WO 02074746	9/26/02	WIPO				
	A74	WO 03000663	1/03/03	WIPO				
	A75	WO 2003/027068	4/03/03	WIPO				
	A76	WO 03/062205	7/31/03	WIPO				
	A77	WO 2003/062392	7/31/03	WIPO				

Examiner Signature	Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-048US1	Application No. 10/576,849
Information Disclosure Statement by Applicant		Applicant Brian Smith, et al.		
	(Use several si (37 CFR §1.98(b))	neets if necessary)	Filing Date April 9, 2007	Group Art Unit

	Foreig	n Patent Documer	ts or Publish	ed Foreign F	atent A	Application	ns	
Examiner	Desig.		Publication	Country or			Translation	
Initial	ID D	Document Number	Date	Patent Office	Class	Subclass	Yes	No
	A78	WO 03086306	10/23/03	WIPO				
	A79	EP 987235	12/03/03	Europe				
	A80	WO 04037788	5/06/04	WIPO				
	A81	WO2005/003096A1	01/13/2005	PCT				
	A82	WO2005/019179A2	03/03/2005	PCT				
	A83	WO2005/042490A1	05/12/2005	PCT				
	A84	WO 2006/013209	2/09/2006	WIPO				
	A85	WO 2006/043710	4/27/2006	WIPO				
	A86	WO2006/069363A2	06/29/06	WIPO				
	A87	WO2006/071740A2	07/06/06	WIPO				

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner	Desig.	
Initial	ID D	Document
	A88	Barnes, T. R., "Pharmacological Strategies for Relapse Prevention in Schizophrenia", <i>Psychiatry</i> 3(10): 37-40 (2004)
	A89	Chahal et al., IDdb Meeting Report 2000, May 17-18
	A90	Chang et al., "Dopamine receptor binding properties of some 2, 3, 4, 5-tetrahydro-1H-3- bergazapine-7-ols with non-aromatic substituents in the 5-position", Bioorg, Med. Chem. Lett. 2:399-402 (1992)
	A91	Deady et al., "Synthesis of some tetrahydro-2-and 3-benzazepines, and of hexahydro-3-benzazocine", Journal of the Chemical Society, Perkins Transactions 1, 1973 pp. 782-783
	A92	Di Chiara G., (2002) Behavioural Brain Research, 137: 75-114
	A93	Di Chiara et al., "Reward System and Addiction: What Dopamine Does and Doesn't Do", Current Opinion in Pharmacology 7:69-76 (2007)
	A94	Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision, Washington, DC, American Psychiatric Association, 2000*
	A95	Di Matteo et al., "Role of 5-HT _{2C} Receptors in the Control of Central Dopamine Function", <i>Trends in Pharmacological Sciences</i> 22(5):229-232 (2001)
A96 Flannery-Schroeder, E. C., "Reducing Anxiety to Prevent Depression", 31(6S1):S136-S142 (2006)		Flannery-Schroeder, E. C., "Reducing Anxiety to Prevent Depression", Am. J. Prev. Med. 31(6S1):S136-S142 (2006)
	A97	Fuchs et al., "Total synthesis of (+',-)-lennoxamine and (+',-)-aphanorphine by intramolecular electrophilic aromatic substitution reactions of 2-amidoacroleins", Organic Letters, 2001, pp. 3923-3925, 3(24) American Chemical Society
	A98	Gallant et al., (1967) Current Therapy Research 9(11):579-81

ı	Examiner Signature	Date Considered
ı		
ı		
ı	EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with
ı	next communication to applicant.	

Application No. Substitute Form PTO-1449 U.S. Department of Commerce Attorney's Docket No. (Modified) Patent and Trademark Office 10/576,849 20750-048US1 Applicant Information Disclosure Statement Brian Smith, et al. by Applicant (Use several sheets if necessary) Filing Date Group Art Unit April 9, 2007 (37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.	1.		
Initial	ID	Document Gardent et al., "Sur quelques de l'amino-2-bromo-4 1H benzazepine-3 et de ses derives", Bull Soc.		
	A99	Chim. France 2:600-605 (1968)		
	A100	Gerace et al., "Predictors of Weight Increases over 7 Years in Fire Fighters and Paramedics", Preventive Medicine 94:593-600 (1996)		
	A101	Gobert et al., (2000) Synapse 36: 205-221		
	A102	Gombar et al., "Pharmacokinetics of a series of 6-chloro-2, 3, 4, 5-tetrahydro-3-substituted-1H-3-benzazepines in rats", Drug Metab. Disposition 16:367-372 (1988)		
	A103	Greene et al., Protective Groups in Organic Syntheses, 2nd Ed., Wiley and Sons, NY (1991)*		
	A104	Halford et al., "Serotonergic Drugs: Effects on Appetite Expression and Use for the Treatment of Obesity", <i>Drugs</i> 67(1):27-55 (2007)		
	A105	Halford, J.C.G., "Obesity Drugs in Clinical Development", Current Opinion in Investigational Drugs 7(4):312-318 (2006)		
	A106	Hassine-Coniac et al., "Preparation et properietes d'aldehydes dans la serie de la benzazapine-3", Bull Soc. Chim. France 11:3985-3992 (1971)		
	A107	Hazebroucq, "Acces a des I-H, tetrahydro-2, 3, 4, 5 benzazepines-3 one-1 et a des hexahydro imidazo isoquinoleines", Ann. Chim. (1966) pp. 221-254		
	A108	Hester et al., (1968) J. Med. Chem. 11(1): 101		
	A109	Higgins et al., (2003) European Journal of Pharmacology, 480: 151		
	A110	Hitzig, P., (1994) Journal of Substance Abuse Treatment, 11(5): 489		
	A111	Im et al., (2003) Molecular Pharmacology, 64: 78-84		
	A112	Jandacck, R.J., "APD-356 (Arcna)", Current Opinion in Investigational Drugs 6(10):1051-1056 (2005)		
	A113	Jenck et al., (1998) European Neuropsychopharmacology 8: 161		
	A114	Jensen et al., "Potential Role of New Therapies in Modifying Cardiovascular Risk in Overweight Patients with Metabolic Risk Facts", Obesity 14 (Suppl. 3):143S-149S (2006)		
	A115	Karasu et al., (2000) Practice Guideline for the Treatment of Patients with Major Depressive Disorder		
	A116	Koplan et al., "Preventing Childhood Obesity: Health in the Balance, Executive Summary", http://www.nap.edu/catalog/11015.html, 41 pages (2005)		
	A117	Krull, O. and Wunesh, B., "Synthesis and Structure/NMDA Receptor Affinity Relationships of 1- Substituted Tetrahydro-3-benzazepines", Bioorganic and Medicinal Chemistry, 12,pp. 1439-1451, 2004.		
	A118	Ladd et al., "Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 2-benzazepines, and 9-(Aminomethyl) fluorenes", J. Med. Chem., Vol. 29:1904-1912 (1986)		
	A119	Lam RW, Levitt AJ (1999) (eds) Canadian Consensus Guidelines for the Treatment of Seasonal Affective Disorder, Clinical & Academic Publishing, Vancouver, BC, Canada		
	A120	Lennon et al., "Azabenzocycloheptenones Part XVIII. Amines and amino-ketones of the tetrahydro- 3-benzazepine-1-one series", J. Chem. Soc. Perkin Transacts. (1975) 7:622-626		
	A121	Linda D. Williams, Chemistry Demystified 123 (2003)		
Examiner Sign	ature	Date Considered		

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-048US1	Application No. 10/576,849
Information Disclosure Statement by Applicant		Applicant Brian Smith, et al.	
(Use several shee	ets if necessary)	Filing Date	Group Art Unit
(37 CFR §1.98(b))		April 9, 2007	

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document	
muai	A122	Macdonald et al., "Design and synthesis of trans-3-(2-4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))-phenyl)carboxamido)cyclohexyl)cthyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): A Potent and selective dopamine D.sub.3 Receptor Antagonist", J. Med. Chem. 46:4952-4964 (2003) American Chemical Society	
	A123	Moline et al., (2001) Expert Consensus Guideline Series – Treatment of Depression in Women 2001, March: 112-113	
	A124	Müller et al., (2006) Trends in Pharmacological Sciences, 27(9): 455 (Abstract)	
	A125	National Institute on Drug Abuse, Proceedings of the 41 st Annual Scientific Meeting (1979) pp. 356-401	
	A126	Navarro-Vazquez et al., "A study of aryl radical cyclization in enaminone esters", J. Org. Chem. 67:3213-20 (2002)	
	A127	Niendam et al., "Neurocognitive Performance and Functional Disability in the Psychosis Prodrome", Schizophrenia Research 84:100-111 (2006)	
	A128	Orioto et al., "Benzolactams—I: Alkylation of 1,2,4,5-tetrahydro-3-methyl-3h-3-benzazepin-2-one with sodium hydride and alkyl halide", Tetrahedron 36:1017-1021 (1980) Pergamon Press Ltd.	
	A129	Orito et al. (Hokkaido Daigaku Kogakubu Kenkyu Hokoku (1979), (96), 41-44	
	A130	Orito et al., "Total synthesis of pseudo type of protopine alkaloids", Heterocycles 14(1) 1980	
	A131	Pauvert et al., "Silver nitrate-promoted ring enlargement of 1-tribromomethyl-1,2-dihydro-and 1- tribromomethyl-1,2,3-4-tetrahydro-isoquinoline derivatives: application to the synthesis of the anti- anginal zalebradine", Tertahedron Letters 44:203-4206 (2003) Pergamon Press Ltd.	
	A132	Pawan et al., (1971) British Journal of Pharmacology, 41(2): 416P-417P (CAPLUS abstract)	
	A133	Pecherer et al., "The Synthesis of Some 7- and 7,8-substituted 2,3,4,5-tetrahydro-1H- 3benzazepines", J. Heterocyclic Chemistry 8(5):779-783 (1971)	
	A134	Perry et al., "Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men", BMJ (1995) 310:560-564	
	A135	Piesla et al., (2001) Schizophrenia Research 49: 95	
	A136	Porras et al., (2002) Neuropsychopharmacology 26: 311-324	
	A137	Prous Science Integrity entry 156186	
	A138	Prous Science Integrity entry 354056	
	A139	Rothman R.B., (1995) Journal of Substance Abuse Treatment, 12(6): 449	
	A140	Schlademan et al., "Synthesis of oxo- and 1-hydroxy-azobenzocycloalkanes", J. Chem. Soc. Perkin Transacts. (1972) 2:213-215	
	A141	Schaffner et al., "Preventing Severe Mental Illnesses – New Prospects and Ethical Challenges", Schizophrenia Research 51:3-15 (2001)	
	A142	Smith et al., "Discovery and SAR of New Benzazepines as Potent and Selective 5-HT _{2C} Receptor Agonists for the Treatment of Obesity", <i>Bioorganic & Medicinal Chemistry Letters</i> 15(5):1467-1470 (2005)	

Examiner Signature	Date Considered
	t in conformance and not considered. Include copy of this form with
next communication to applicant.	
	Substitute Disclosure Form (PTO-1449)
	Examiner Signature EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-048US1	Application No. 10/576,849
Information Disclosure Statement by Applicant		Applicant Brian Smith, et al.	
(Use several she (37 CFR §1.98(b))	eets if necessary)	Filing Date April 9, 2007	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Desig.		
Initial	ID	Document
	A143	Smith, B. M. et al., "Discovery and Structure – Activity Relationship of (I/R)-8-Chloro-2,3,4,5-tertalydro-1-rehdyl-I/R-3-benzaezpine (Lorrasacin), a Selective Serotonin 5-HT _{2e} Receptor Agonist for the Treatment of Obesity", [retrieved on 12/21/07]. Retrieved from the Internet. <u>CRL:http://pubs.acs.org/journals/incmar/index.html</u> >.
		Tietz et al., "Efficient synthesis of 2, 3, 4, 5-tetrahydro-1H-3-benzazepines by intramolecular Heck reaction", Synthesis (1993) 9:876-880
	A145	Tietze et al., "Efficient synthesis of 2,34,5-tetrahydro-1H-3-benzazepines by intramolecular heck reaction", Institut für Organische Chemie der Universität Göttingen, Tammannstraße 2, D-3400 Göttingen, Germany, received January 29, 1993.
	A146	Tsuang et al., "Towards the Prevention of Schizophrenia", Biol. Psychiatry 48:349-356 (2000)
	A147	Vink et al., "Risk Factors for Anxiety and Depression in the Elderly: A Review", J. Affect. Disord., doi:10.1016/j.jad.2007.06.005, 16 pages (2007)
A150 Overweight Condition", Preventive Medicine 38:172-174 (2004)		Wise, R.A., (2000) Neuron, 26: 27-33
		Wisner et al., (2002) N. Engl. J. Med., 347(3): 194-199
		Yoshinaga et al., "Prevention of Mildly Overweight Children from Development of More Overweight Condition", Preventive Medicine 38:172-174 (2004)
		International Search Report dated February 2,, 2005 for International Application No. PCT/US2004/034917.

	Examiner Signature	Date Considered	
	EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form w		
next communication to applicant.			